SCHEMBL20148623

SCHEMBL20148623

CC(C)(C)N1CC2CC(C1)N2Cc1ccc(F)cn1

nearest known ligand 0.41

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
RET P07949 4/20 0.41
TRPC6 Q9Y210 1/20 0.33
CNR2 P34972 1/20 0.32
HTR2A P28223 4/20 0.31
PDE1C Q14123 1/20 0.31
GRM2 Q14416 1/20 0.31
KCNH2 Q12809 2/20 0.30
TLR7 Q9NYK1 1/20 0.30
PRCP P42785 1/20 0.30
JAK2 O60674 1/20 0.30
JAK1 P23458 1/20 0.30
JAK3 P52333 1/20 0.30
RIPK1 Q13546 1/20 0.30
CYP1A2 P05177 1/20 0.30
HTR2C P28335 1/20 0.30
CYP2C19 P33261 1/20 0.30
HTR2B P41595 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22812017 0.85 RET (0.44) RETTRPC6HTR2AKCNH2TLR7
SCHEMBL20148649 0.84 RET (0.40) RET
SCHEMBL20069645 0.82 RET (0.42) RETTRPC6HTR2AGRM2KCNH2
SCHEMBL20148629 0.82 RET (0.45) RET
SCHEMBL20149602 0.81 RET (0.41) RETTRPC6CNR2HTR2A
SCHEMBL20148686 0.79 RET (0.39) RETPDE1CTLR7
SCHEMBL20160378 0.79 RET (0.46) RETHTR2AKCNH2
SCHEMBL20148624 0.78 LMNA (0.41) RETKCNH2CYP1A2CYP2C19
SCHEMBL20148671 0.77 RET (0.43) RETCYP1A2
SCHEMBL20148645 0.76 RET (0.42) RET

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180133200-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS ARRAY BIOPHARMA INC. 2018-05-17 US disclosed
US-20180133200-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS ARRAY BIOPHARMA INC. 2018-05-17 US disclosed
US-20180134702-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS ARRAY BIOPHARMA INC. 2018-05-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180134702-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS RET, ROR1, BRAF RET 1/4885TRPC6 3489/4885CNR2 4312/4885
US-20180133200-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS RET, ROR1, BRAF RET 1/4885TRPC6 3489/4885CNR2 4312/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.